Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00381706
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Columbus, Ohio
- New York, New York
- Norwalk, Connecticut
- Lewes, Delaware
- Newark, Delaware
- Washington, District of Columbia
- Aurora, Illinois
- Bloomington, Illinois
- Canton, Illinois
- Carthage, Illinois
- Chicago, Illinois
- Decatur, Illinois
- Eureka, Illinois
- Evanston, Illinois
- Galesburg, Illinois
- Galesburg, Illinois
- Harvey, Illinois
- Havana, Illinois
- Hopedale, Illinois
- Joliet, Illinois
- Macomb, Illinois
- Normal, Illinois
- Normal, Illinois
- Ottawa, Illinois
- Ottawa, Illinois
- Pekin, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Peru, Illinois
- Princeton, Illinois
- Rockford, Illinois
- Spring Valley, Illinois
- Springfield, Illinois
- Urbana, Illinois
- Urbana, Illinois
- Elkhart, Indiana
- Fort Wayne, Indiana
- Indianapolis, Indiana
- Indianapolis, Indiana
- Kokomo, Indiana
- La Porte, Indiana
- Michigan City, Indiana
- South Bend, Indiana
- South Bend, Indiana
- South Bend, Indiana
- South Bend, Indiana
- Ames, Iowa
- Bettendorf, Iowa
- Cedar Rapids, Iowa
- Cedar Rapids, Iowa
- Des Moines, Iowa
- Des Moines, Iowa
- Des Moines, Iowa
- Des Moines, Iowa
- Des Moines, Iowa
- Des Moines, Iowa
- Des Moines, Iowa
- Iowa City, Iowa
- Mason City, Iowa
- Ottumwa, Iowa
- Sioux City, Iowa
- Sioux City, Iowa
- Sioux City, Iowa
- West Des Moines, Iowa
- Anthony, Kansas
- Chanute, Kansas
- Dodge City, Kansas
- El Dorado, Kansas
- Fort Scott, Kansas
- Independence, Kansas
- Kingman, Kansas
- Lawrence, Kansas
- Liberal, Kansas
- Newton, Kansas
- Overland Park, Kansas
- Parsons, Kansas
- Pratt, Kansas
- Salina, Kansas
- Shawnee Mission, Kansas
- Wellington, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Winfield, Kansas
- Bangor, Maine
- Baltimore, Maryland
- Easton, Maryland
- Elkton MD, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Burlington, Massachusetts
- South Weymouth, Massachusetts
- Springfield, Massachusetts
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Dearborn, Michigan
- Escanaba, Michigan
- Flint, Michigan
- Flint, Michigan
- Grosse Pointe Woods, Michigan
- Iron Mountain, Michigan
- Jackson, Michigan
- Kalamazoo, Michigan
- Kalamazoo, Michigan
- Kalamazoo, Michigan
- Lansing, Michigan
- Livonia, Michigan
- Pontiac, Michigan
- Port Huron, Michigan
- Saginaw, Michigan
- Saint Joseph, Michigan
- St. Joseph, Michigan
- Warren, Michigan
- Burnsville, Minnesota
- Coon Rapids, Minnesota
- Duluth, Minnesota
- Duluth, Minnesota
- Duluth, Minnesota
- Edina, Minnesota
- Fridley, Minnesota
- Hutchinson, Minnesota
- Lichfield, Minnesota
- Maplewood, Minnesota
- Maplewood, Minnesota
- Minneapolis, Minnesota
- Minneapolis, Minnesota
- Minneapolis, Minnesota
- Robbinsdale, Minnesota
- Saint Louis Park, Minnesota
- Saint Louis Park, Minnesota
- Saint Paul, Minnesota
- Shakopee, Minnesota
- St. Paul, Minnesota
- Waconia, Minnesota
- Woodbury, Minnesota
- Independence, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Liberty, Missouri
- Saint Joseph, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Omaha, Nebraska
- Omaha, Nebraska
- Omaha, Nebraska
- Omaha, Nebraska
- Omaha, Nebraska
- Las Vegas, Nevada
- Las Vegas, Nevada
- Lebanon, New Hampshire
- Marlton, New Jersey
- Newark, New Jersey
- Sparta, New Jersey
- Voorhees, New Jersey
- Voorhees, New Jersey
- Bronx, New York
- Buffalo, New York
- East Syracuse, New York
- Glens Falls, New York
- New York, New York
- New York, New York
- Chapel Hill, North Carolina
- Charlotte, North Carolina
- Goldsboro, North Carolina
- Hendersonville, North Carolina
- Kinston, North Carolina
- Akron, Ohio
- Canton, Ohio
- Cleveland, Ohio
- Columbus, Ohio
- Lima, Ohio
- Allentown, Pennsylvania
- Bethlehem, Pennsylvania
- Danville, Pennsylvania
- East Stroudsburg, Pennsylvania
- Hazleton, Pennsylvania
- Hershey, Pennsylvania
- Lewistown, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Scranton, Pennsylvania
- State College, Pennsylvania
- State College, Pennsylvania
- Wilkes-Barre, Pennsylvania
- Wilkes-Barre, Pennsylvania
- Williamsport, Pennsylvania
- Florence, South Carolina
- Sioux Falls, South Dakota
- Sioux Falls, South Dakota
- Sioux Falls, South Dakota
- Kingsport, Tennessee
- Temple, Texas
- Berlin, Vermont
- Burlington, Vermont
- Danville, Virginia
- Norton, Virginia
- Eau Claire, Wisconsin
- Eau Claire, Wisconsin
- Green Bay, Wisconsin
- Green Bay, Wisconsin
- Green Bay, Wisconsin
- Green Bay, Wisconsin
- Marinette, Wisconsin
- Marshfield, Wisconsin
- Milwaukee, Wisconsin
- Minocqua, Wisconsin
- Oconto Falls, Wisconsin
- Rhinelander, Wisconsin
- Rice Lake, Wisconsin
- Stevens Point, Wisconsin
- Sturgeon Bay, Wisconsin
- Wausau, Wisconsin
- Wausau, Wisconsin
- Weston, Wisconsin
- Wisconsin Rapids, Wisconsin
- Ottawa, Ontario
- Toronto, Ontario
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | |||
Official Title ICMJE | Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer | |||
Brief Summary | RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one chemotherapy drug (combination chemotherapy) together with cetuximab may kill more tumor cells. PURPOSE: This randomized phase II trial is studying three different combination chemotherapy regimens to compare how well they work when given together with cetuximab in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer. | |||
Detailed Description | OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histology (squamous cell carcinoma vs adenocarcinoma) and Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 vs 2). Patients are randomized to 1 of 3 treatment arms. For more information please see the "Arms" section which includes a detailed description of the treatment regimens. The primary objective of the study is evaluate the tumor response rate (RR) for each of the regimens in this trial and to select the most promising regimen based on RR for further testing in patients with metastatic esophageal or GE junction adenocarcinoma. The secondary objectives are:
All subjects must be premedicated with diphenhydramine hydrochloride 50 mg IV (or a similar agent) prior to the first dose of cetuximab in an effort to minimize infusion and hypersensitivity reactions. Premedication is recommended prior to subsequent doses, but the dose of diphenhydramine (or similar agent) may be reduced at the investigator's discretion. More information is detailed in the protocol including a description of the premedication requirements. Patients were closely monitored for treatment-related adverse events. After completion of study treatment, patients are followed periodically for up to 2 years. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Esophageal Cancer | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 245 | |||
Original Enrollment ICMJE | Not Provided | |||
Study Completion Date ICMJE | Not Provided | |||
Actual Primary Completion Date | April 2011 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE |
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00381706 | |||
Other Study ID Numbers ICMJE | CALGB-80403 ECOG-E1206 CDR0000505535 ( Other Identifier: Physician Data Query ) NCI-2009-00492 ( Other Identifier: NCI Clinical Trial Reporting Program ) | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Alliance for Clinical Trials in Oncology | |||
Study Sponsor ICMJE | Alliance for Clinical Trials in Oncology | |||
Collaborators ICMJE |
| |||
Investigators ICMJE |
| |||
PRS Account | Alliance for Clinical Trials in Oncology | |||
Verification Date | January 2017 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |